On April 7, GeneMatrix(CEO Soo-Ok Kim), a Korean company servicing molecular diagnostics, announced that it had signed an export contract with Italy for its COVID-19 detection kit, "NeoPlex™ COVID-19."

With this agreement, GeneMatrix will supply NeoPlex COVID-19 to Italy in earnest. The contract amount is US$288,000, which is about 1.5 times higher than the previous contract.

GeneMatrix stated, "Italy is now one of the most affected regions of COVID-19 in Europe, and there is a continuing need for test kits. After the product was supplied to Italy in March, we verified the accuracy and reliability of NeoPlex COVID-19 in the field and achieved an additional order contract."

GeneMatrix signed a contract for the supply of NeoPlex COVID-19 worth of US$472,000 to the UAE last month, and on the 6th of this month, an additional agreement of US$450,000 was closed. NeoPlex COVID-19 is explained to have been well received in the field because it performs a batch examination with one tube, and analyzes accurately, easily, and quickly.

The company said, "The continuous sales are also generated in the Middle East by securing trust in the products and closing additional contracts. GeneMatrix is currently working closely with diagnostic companies from around the world to proceed with exports to Europe and the United States."